[Raynaud's phenomenon following combined cytostatic treatment of malignant testicular tumours].
Raynaud's phenomenon was observed in 8 out of 271 patients with malignant testicular tumours during or up to 14 months after combined cytostatic treatment. All patients with Raynaud's phenomenon were part of a group of 30 people having received vinblastine in a total dose of at least 2 mg/kg and bleomycin in a dose of 10 mg/kg. There were no other hints of Raynaud's syndrome from the history or chemical pathology. Compared to the experience of other authors Raynaud's phenomenon was observed less frequently and only at dosages of vinblastine and bleomycin considerably higher. This may possibly be due to use of steroids during combined cytostatic treatment with vinblastine and bleomycin.
D000328:Adult; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011928:Raynaud Disease / Q000139:chemically induced*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects*
D001761:Bleomycin; D014747:Vinblastine
Raynaud-Syndrom nach kombinierter zytostatischer Behandlung von Patienten mit malignen Hodentumoren.